Featured Research

from universities, journals, and other organizations

Use of anti-fungal drug for premature infants clarified

Date:
May 4, 2014
Source:
Duke Medicine
Summary:
In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings of a new study. The research clarifies a choice faced by doctors treating the tiniest of newborns whose fragile immune systems are vulnerable to Candida infections: Routinely administer anti-fungal medicine to babies weighing less than 2 pounds regardless of whether they have an infection; or hold off using the drugs until an infection occurs.

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team.

The research clarifies a choice faced by doctors treating the tiniest of newborns whose fragile immune systems are vulnerable to Candida infections: Routinely administer anti-fungal medicine to babies weighing less than 2 pounds regardless of whether they have an infection; or hold off using the drugs until an infection occurs.

Studying these patients to determine the best approach has been difficult, and previous studies had limitations. The current research -- part of the Pediatric Trials Network initiative led by the Duke Clinical Research Institute -- now provides a strong scientific basis to guide neonatal doctors facing a common treatment decision.

"There has been some controversy about whether to use the drug fluconazole as a routine preventive for candidiasis," said lead author Daniel K. Benjamin Jr., M.D., Ph.D., professor of pediatrics at Duke. "Previous studies found a benefit, but they looked at reducing infections at centers with high rates of disease. Most neonatal intensive care units in the United States and Europe have low rates of disease, so questions have remained about whether the risks of using the drug among these babies are justified."

Benjamin said at most, a third of neonatal units in the United States routinely give fluconazole to extremely premature infants, which are those born earlier than 32 weeks gestation. But the question lingers about using the drug as a preventive, given potential side effects.

Publishing in the May 7, 2014, issue of the Journal of the American Medical Association, Benjamin and colleagues reported that the use of fluconazole did not significantly reduce the combined risk of death or invasive candidiasis, a lethal fungal infection that kills or impairs nearly 70 percent of the extremely premature babies it strikes.

The finding was based on a randomized, prospective study involving 32 U.S. neonatal intensive care units. Researchers enrolled 361 extremely premature infants, randomizing roughly half to receive fluconazole twice weekly for 42 days, and the other half to get a placebo.

While fewer infants who received fluconazole developed candidiasis, the death rate between the two groups was the same -- 14 percent -- leading to a composite finding that the drug did not provide a statistically significant benefit for infants treated at centers with a low incidence of infection.

"It's important to stress that using the drug to prevent the spread of infection in units with moderate to high rates of disease should continue, based on our findings," said senior author P. Brian Smith, M.D., MPH, MHS, associate professor of pediatrics at Duke. "But most babies should not be routinely put on the drug prophylactically."

Smith added that the researchers found no long-term neurological problems associated with using fluconazole, which had been a concern of doctors. With two years of follow-up, the research team found no difference in neurological outcomes between infants who took the preventive medicine and those receiving placebo.

Benjamin said the study's findings fill in missing information that doctors have needed to guide care for children -- a key goal of the Pediatric Trials Network that was established in 2010 with a $95 million, seven-year investment by the National Institutes of Health to determine the best drug choices and dosages for children.

The Duke Clinical Research Institute was selected to lead the network. Since that time, dozens of multi-institutional studies have been launched, and findings are now being published.

"We are plugging away at this bit-by-bit to determine the proper way to treat children," said Benjamin, who is principal investigator of the network. "We are turning the crank on all sorts of things that will make the lives of children better."


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Daniel K. Benjamin, Mark L. Hudak, Shahnaz Duara, David A. Randolph, Margarita Bidegain, Gratias T. Mundakel, Girija Natarajan, David J. Burchfield, Robert D. White, Karen E. Shattuck, Natalie Neu, Catherine M. Bendel, M. Roger Kim, Neil N. Finer, Dan L. Stewart, Antonio C. Arrieta, Kelly C. Wade, David A. Kaufman, Paolo Manzoni, Kristi O. Prather, Daniela Testoni, Katherine Y. Berezny, P. Brian Smith. Effect of Fluconazole Prophylaxis on Candidiasis and Mortality in Premature Infants. JAMA, 2014; 311 (17): 1742 DOI: 10.1001/jama.2014.2624

Cite This Page:

Duke Medicine. "Use of anti-fungal drug for premature infants clarified." ScienceDaily. ScienceDaily, 4 May 2014. <www.sciencedaily.com/releases/2014/05/140504095236.htm>.
Duke Medicine. (2014, May 4). Use of anti-fungal drug for premature infants clarified. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/05/140504095236.htm
Duke Medicine. "Use of anti-fungal drug for premature infants clarified." ScienceDaily. www.sciencedaily.com/releases/2014/05/140504095236.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins